Prolonged Survival in Patients with Metastatic HER2-Positive Inflammatory Breast Cancer: A Case Report and Review of the Literature

por Ge, Jennifer Y., Overmoyer, Beth
Publicado no Case Rep Oncol (2021)

Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study

por Jagsi, Reshma, Griffith, Kent A., Bellon, Jennifer R., Woodward, Wendy A., Horton, Janet K., Ho, Alice, Feng, Felix Y., Speers, Corey, Overmoyer, Beth, Sabel, Michael, Schott, Anne F., Pierce, Lori
Publicado no J Clin Oncol (2018)

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)

por Golshan, Mehra, Cirrincione, Constance T., Sikov, William M., Carey, Lisa A., Berry, Donald A., Overmoyer, Beth, Henry, Nora L., Somlo, George, Port, Elisa, Burstein, Harold J., Hudis, Clifford, Winer, Eric, Ollila, David W.
Publicado no Breast Cancer Res Treat (2016)

Prospective clinical experience with research biopsies in breast cancer patients

por Vaz-Luis, Ines, Zeghibe, Catherine A., Frank, Elizabeth S., Sohl, Jessica, Washington, Kimberly E., Silverman, Stuart G., Fonte, Joseph M., Mayer, Erica L., Overmoyer, Beth A., Richardson, Andrea L., Krop, Ian E., Winer, Eric P., Lin, Nancy U.
Publicado em 2013

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer

por Tolaney, Sara M., Tan, Sally, Guo, Hao, Barry, William, Van Allen, Eliezer, Wagle, Nikhil, Brock, Jane, Larrabee, Katherine, Paweletz, Cloud, Ivanova, Elena, Janne, Pasi, Overmoyer, Beth, Wright, John J., Shapiro, Geoffrey I., Winer, Eric P., Krop, Ian E.
Publicado no Invest New Drugs (2015)

A Vasculature-Targeting Regimen of Pre-Operative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers

por Baar, Joseph, Silverman, Paula, Lyons, Janice, Fu, Pingfu, Abdul-Karim, Fadi, Ziats, Nicholas, Wasman, Jay, Hartman, Paul, Jesberger, John, Dumadag, Leda, Hohler, Erin, Leeming, Rosemary, Shenk, Robert, Chen, Helen, McCrae, Keith, Dowlati, Afshin, Remick, Scot C., Overmoyer, Beth
Publicado em 2009

Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine

por Krishnamurthi, Smitha S., Brell, Joanna M., Hoppel, Charles L., Egorin, Merrill J., Weaver, Karen C., Li, Xiaolin, Ingalls, Stephen T., Zuhowski, Eleanor G., Schluchter, Mark D., Dowlati, Afshin, Cooney, Matthew M., Gibbons, Joseph, Overmoyer, Beth A., Ivy, S. Percy, Remick, Scot C.
Publicado no Cancer Chemother Pharmacol (2008)

Kinetic-Pharmacodynamic Model of Chemotherapy Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel or Ixabepilone: CALGB...

por Mehrotra, Shailly, Sharma, Manish R., Gray, Elizabeth, Wu, Kehua, Barry, William T., Hudis, Clifford, Winer, Eric P., Lyss, Alan P., Toppmeyer, Deborah L., Moreno-Aspitia, Alvaro, Lad, Thomas E., Valasco, Mario, Overmoyer, Beth, Rugo, Hope, Ratain, Mark J., Gobburu, Jogarao V.
Publicado no AAPS J (2017)

Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)

por Sharma, Manish R., Mehrotra, Shailly, Gray, Elizabeth, Wu, Kehua, Barry, William T., Hudis, Clifford, Winer, Eric P., Lyss, Alan P., Toppmeyer, Deborah L., Moreno-Aspitia, Alvaro, Lad, Thomas E., Velasco, Mario, Overmoyer, Beth, Rugo, Hope S., Ratain, Mark J., Gobburu, Jogarao V.
Publicado no J Clin Pharmacol (2019)

Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer

por Stover, Daniel G., Gil Del Alcazar, Carlos R., Brock, Jane, Guo, Hao, Overmoyer, Beth, Balko, Justin, Xu, Qiong, Bardia, Aditya, Tolaney, Sara M., Gelman, Rebecca, Lloyd, Maxwell, Wang, Yu, Xu, Yaomin, Michor, Franziska, Wang, Vivian, Winer, Eric P., Polyak, Kornelia, Lin, Nancy U.
Publicado no NPJ Breast Cancer (2018)

A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance)

por Rashkin, Sara R., Chua, Katherina C., Ho, Carol, Mulkey, Flora, Jiang, Chen, Mushiroda, Tasei, Kubo, Michiaki, Friedman, Paula N., Rugo, Hope S., McLeod, Howard L., Ratain, Mark J., Castillos, Francisco, Naughton, Michael, Overmoyer, Beth, Toppmeyer, Deborah, Witte, John S., Owzar, Kouros, Kroetz, Deanna L.
Publicado no Clin Pharmacol Ther (2018)

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients

por Tolaney, Sara M., Ziehr, David R., Guo, Hao, Ng, Mei R., Barry, William T., Higgins, Michaela J., Isakoff, Steven J., Brock, Jane E., Ivanova, Elena V., Paweletz, Cloud P., Demeo, Michelle K., Ramaiya, Nikhil H., Overmoyer, Beth A., Jain, Rakesh K., Winer, Eric P., Duda, Dan G.
Publicado no Oncologist (2017)

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

por Tolaney, Sara M., Barry, William T., Dang, Chau T., Yardley, Denise A., Moy, Beverly, Marcom, P. Kelly, Albain, Kathy S., Rugo, Hope S., Ellis, Matthew, Shapira, Iuliana, Wolff, Antonio C., Carey, Lisa A., Overmoyer, Beth A., Partridge, Ann H., Guo, Hao, Hudis, Clifford A., Krop, Ian E., Burstein, Harold J., Winer, Eric P.
Publicado no N Engl J Med (2015)

Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Cli...

por Tolaney, Sara M., Barroso-Sousa, Romualdo, Keenan, Tanya, Li, Tianyu, Trippa, Lorenzo, Vaz-Luis, Ines, Wulf, Gerburg, Spring, Laura, Sinclair, Natalie Faye, Andrews, Chelsea, Pittenger, Jessica, Richardson, Edward T., Dillon, Deborah, Lin, Nancy U., Overmoyer, Beth, Partridge, Ann H., Van Allen, Eliezer, Mittendorf, Elizabeth A., Winer, Eric P., Krop, Ian E.
Publicado no JAMA Oncol (2020)

Chemotherapy-Related Amenorrhea after Adjuvant Paclitaxel-Trastuzumab (APT Trial)

por Ruddy, Kathryn J., Guo, Hao, Barry, William, Dang, Chau T., Yardley, Denise A., Moy, Beverly, Marcom, P. Kelly, Albain, Kathy S., Rugo, Hope S., Ellis, Matthew J., Shapira, Iuliana, Wolff, Antonio C., Carey, Lisa A., Overmoyer, Beth A., Hudis, Clifford, Krop, Ian E., Burstein, Harold J., Winer, Eric P., Partridge, Ann H., Tolaney, Sara M.
Publicado no Breast Cancer Res Treat (2015)

International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference

por Ueno, Naoto T., Espinosa Fernandez, Jose Rodrigo, Cristofanilli, Massimo, Overmoyer, Beth, Rea, Dan, Berdichevski, Fedor, El-Shinawi, Mohamad, Bellon, Jennifer, Le-Petross, Huong T., Lucci, Anthony, Babiera, Gildy, DeSnyder, Sarah M., Teshome, Mediget, Chang, Edward, Lim, Bora, Krishnamurthy, Savitri, Stauder, Michael C, Parmar, Simrit, Mohamed, Mona M, Alexander, Angela, Valero, Vicente, Woodward, Wendy A.
Publicado no J Cancer (2018)

Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10(th) Anniversary Conference

por Woodward, Wendy A., Cristofanilli, Massimo, Merajver, Sofia D., Van Laere, Steven, Pusztai, Lajos, Bertucci, Francois, Berditchevski, Fedor, Polyak, Kornelia, Overmoyer, Beth, Devi, Gayathri R., Sterneck, Esta, Schneider, Robert, Debeb, Bisrat G., Wang, Xiaoping, van Golen, Kenneth L., El-Zein, Randa, Rahal, Omar M., Alexander, Angela, Reuben, James M., Krishnamurthy, Savitri, Lucci, Anthony, Ueno, Naoto T.
Publicado no J Cancer (2017)

Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium

por Devi, Gayathri R., Hough, Holly, Barrett, Nadine, Cristofanilli, Massimo, Overmoyer, Beth, Spector, Neil, Ueno, Naoto T., Woodward, Wendy, Kirkpatrick, John, Vincent, Benjamin, Williams, Kevin P., Finley, Charlotte, Duff, Brandi, Worthy, Valarie, McCall, Shannon, Hollister, Beth A., Palmer, Greg, Force, Jeremy, Westbrook, Kelly, Fayanju, Oluwadamilola, Suneja, Gita, Dent, Susan F., Hwang, E. Shelley, Patierno, Steven R., Marcom, P. Kelly
Publicado no J Cancer (2019)

Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer (mTNBC)

por Keenan, Tanya E., Li, Tianyu, Vallius, Tuulia, Guerriero, Jennifer L., Tayob, Nabihah, Kochupurakkal, Bose, Davis, Janae, Pastorello, Ricardo, Tahara, Rie K., Anderson, Leilani, Conway, Jake, He, Meng X., Shannon, Erin, Godin, Robert E., Sorger, Peter K., D’Andrea, Alan, Overmoyer, Beth, Winer, Eric P., Mittendorf, Elizabeth A., Van Allen, Eliezer M., Shapiro, Geoffrey I., Tolaney, Sara M.
Publicado no Clin Cancer Res (2020)

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

por Tolaney, Sara M., Guo, Hao, Pernas, Sonia, Barry, William T., Dillon, Deborah A., Ritterhouse, Lauren, Schneider, Bryan P., Shen, Fei, Fuhrman, Kit, Baltay, Michele, Dang, Chau T., Yardley, Denise A., Moy, Beverly, Marcom, P. Kelly, Albain, Kathy S., Rugo, Hope S., Ellis, Mathew J., Shapira, Iuliana, Wolff, Antonio C., Carey, Lisa A., Overmoyer, Beth, Partridge, Ann H., Hudis, Clifford A., Krop, Ian E., Burstein, Harold J., Winer, Eric P.
Publicado no J Clin Oncol (2019)